Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC and AS chemotherapy in gastric or esophagogastric junction adenocarcinoma
NCT05095467Phase 2Not yet recruiting
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nab-paclitaxel, tegafur-gimeracil-oteracil in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), peritoneal metastasis (PM). Planned start Oct 2021; status: not yet recruiting.
02
Drugs
nab-paclitaxeltegafur-gimeracil-oteracil
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)peritoneal metastasis (PM)
Beyond the preview
Go deeper on NCT05095467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095467.